APA (7th ed.) Citation

C, G., K, S., J, C., S, K., K, M., K, N., . . . MJ, S. (2021). Systemic administration of IL-33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma. Immunology and cell biology, 99(1), 65. https://doi.org/10.1111/imcb.12390

Chicago Style (17th ed.) Citation

C, Guillerey, et al. "Systemic Administration of IL-33 Induces a Population of Circulating KLRG1hi Type 2 Innate Lymphoid Cells and Inhibits Type 1 Innate Immunity Against Multiple Myeloma." Immunology and Cell Biology 99, no. 1 (2021): 65. https://doi.org/10.1111/imcb.12390.

MLA (9th ed.) Citation

C, Guillerey, et al. "Systemic Administration of IL-33 Induces a Population of Circulating KLRG1hi Type 2 Innate Lymphoid Cells and Inhibits Type 1 Innate Immunity Against Multiple Myeloma." Immunology and Cell Biology, vol. 99, no. 1, 2021, p. 65, https://doi.org/10.1111/imcb.12390.